Roche and NuGEN Technologies Develop Whole Transcriptome Profiling Solution for 454 Sequencing Systems
Branford, CT and San Carlos, CA, USA, 05. April 2011
Roche and NuGEN Technologies to co-promote NuGEN’s Ovation RNA-Seq System with the GS FLX and GS Junior Systems to enable whole transcriptome profiling with low abundance RNA samples.
454 Life Sciences, a Roche Company, and NuGEN Technologies, announced today the development of a unique sample preparation method and high-throughput sequencing solution for small and degraded RNA samples. The collaboration leverages 454 Life Sciences’ capabilities to construct sequencing-ready cDNA libraries from RNA samples and NuGEN’s experience and innovation with genomic sample preparation solutions. This collaborative effort provides researchers an end-to-end solution for transcriptome profiling using their most precious sample types.
Rare and difficult to obtain samples present a unique challenge to researchers who must maximize the utility of low abundance sample. Typical cDNA protocols often require up to 20 µg of input material which limits use to samples with large quantities of RNA available. Under the collaborative relationship, the two companies have developed a solution using both NuGEN’s proprietary isothermal linear amplification (SPIA) products and the GS FLX Titanium cDNA Rapid Library Preparation protocol for the GS Junior and GS FLX Systems.
“NuGEN’s innovative sample preparation solutions provide a unique and powerful tool which will enable researchers to obtain high-quality data from their less abundant samples,” said Elizabeth Hutt, CEO of NuGEN Technologies. “Together with 454 Sequencing Systems, the research community can perform whole transcriptome profiling on samples with as little as 500 pg of total RNA. Being able to collaborate with a leading NGS platform provider such as Roche, enables customers to leverage NuGEN’s linear amplification technology while obtaining long and highly accurate sequence reads.”
“We are sensitive to the challenges many researchers face when working with precious and often irreplaceable samples,” said Todd E. Arnold, Ph.D., Vice President of Development at 454 Life Sciences, a Roche Company. “By combining NuGEN’s amplification technology with 454 Sequencing Systems, we provide a solution that meets these researchers’ needs, while allowing them to leverage the power of 454 Sequencing System’s long read lengths which are critical for both de novo transcriptome assembly and comprehensive identification of splice variants and fusion transcripts.”
For more information on 454 Sequencing Systems, visit www.454.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
NuGEN Technologies, Inc. provides revolutionary RNA and DNA sample preparation technologies that enable life scientists to do more with less. With innovative reagent solutions that are quick and easy to use, NuGEN empowers researchers to prepare genomic samples of any size, from almost any source, regardless of the intended application or technology platform. Committed to advancing the life sciences, NuGEN ensures robust and reproducible results for researchers seeking to predict disease risk and drug response, potentially shortening the path to treatment. For more information, please visit www. nugeninc.com
For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, 454 SEQUENCING, GS FLX, GS FLX TITANIUM and GS JUNIOR are trademarks of Roche.
Other brands or product names are trademarks of their respective holders.